A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

NCT02501161 · Completed

Last updated 2026-05-28

This clinical trial compared the long-term blood sugar control of two diabetes treatments—insulin degludec/liraglutide (IDegLira) and insulin glargine—in adults with type 2 diabetes over 104 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 1,012 people

Who can join Ages 18+ · all sexes

Timeline Started 2016-01 · est. completion 2018-10

Where 143 sites · Argentina, Brazil, Czechia, Hungary, India, Israel, Italy, Mexico, Norway, Poland, Russia, Slovakia, South Africa, Turkey (Türkiye), United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT02501161 ↗

Description as written by the study sponsor.

This trial is conducted in Africa, Asia, Europe, North America and South America. The purpose is to compare long-term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) in insulin naïve subjects with type 2 diabetes mellitus inadequately controlled with oral anti diabetics.

Treatments tested

insulin degludec/liraglutide Drug

Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
insulin glargine Drug

Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.

Main thing measured	Time From Randomisation to Inadequate Glycaemic Control and Need for Treatment Intensification
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02501161 ↗